Close Menu

NEW YORK – University of Pennsylvania researchers have validated a gold nanoparticle-based lateral flow assay for fentanyl screening at the point of care.

Designed to provide results in five minutes wherever a patient is located, the test would fill an unmet clinical need by enabling quick identification of patients who have overdosed using the lethal drug, said test developer Ping Wang, an associate professor of pathology and laboratory medicine at the University of Pennsylvania.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.